New Two-Pronged drug aims to shrink tumors before surgery
NCT ID NCT04556253
Summary
This study is testing an experimental immunotherapy drug called AK104 for people with locally advanced stomach or colorectal cancer that has a specific genetic feature (MSI-H/dMMR). Participants receive the drug for three cycles before surgery and up to six months after surgery. The main goal is to see if the treatment can completely eliminate cancer cells in the surgically removed tissue.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H/DMMR GASTRIC CARCINOMA AND COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, 100142, China
Conditions
Explore the condition pages connected to this study.